4D pharma will present preclinical data on its immuno-oncology programme at the Cell-Weizmann Institute of Science Symposium: Next Gen Immunology meeting from February 11 - 14 in Rehovot, Israel. The company will present a poster on its lead candidate, MRx0518, a single-strain live biotherapeutic under investigation for the treatment of a range of solid tumour types, which is set to hit the clinic in 2018.
The data presented are:
Live biotherapeutics and immuno-oncology: from discovery to efficacy studies, presented by Anna Etorre, PhD, 4D Pharma Research.
Download PDF (920 KB)